Study finds two bowel diseases differ, linking one to higher colon cancer risk

New research from the Garvan Institute of Medical Research has shown that two closely related bowel diseases, long treated with the same therapeutic protocols, are in fact fundamentally distinct. The study, published in a peer‑reviewed journal, is the first to demonstrate clear biological differences between the conditions, shedding light on why one of them carries a markedly higher risk of developing colon cancer.

The investigators performed a comprehensive molecular analysis of tissue samples from patients with each disease, revealing divergent pathways of inflammation and cellular proliferation. These differences explain the disparate cancer risks and underscore the inadequacy of a one‑size‑fits‑all approach to treatment. The findings suggest that clinicians should consider disease‑specific strategies, potentially incorporating targeted therapies that address the unique mechanisms uncovered by the Garvan Institute’s research.